Brief: Algernon Files Meeting Request With Mhra For Use Of Dmt In Phase 1/2A Human Stroke Study
13/10/2021 12:07
Oct 13 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON FILES MEETING REQUEST WITH MHRA FOR USE OF DMT IN
PHASE
1/2A HUMAN STROKE STUDY
Source text for Eikon: ID:nGNX8HrLBh
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement